A message for our valued healthcare professionals:
ArcMesa Educators is very pleased to announce that we are expanding our learning communities and improving our website so we can offer the most effective and convenient learning experience for the healthcare professional.

If you are a returning registrant and wish to check your earned credit history or print certificates for courses you have completed with ArcMesa Educators, we welcome you back and request that you please click here to access our login page.  If you are new to our site, we welcome you to join us and your colleagues who have already discovered the longest running, fully-accredited provider of CME / CE activities on the internet -- where we learn, share and teach. 

Thank you for making us part of a shared goal to improve patient care and quality of life!

-The ArcMesa Educators Team

Osteoporosis: Opportunity for Better Outcomes
Faculty: Felicia Cosman, MD | Nelson B. Watts, MD | Michael R. McClung, MD | Kenneth W. Lyles, MD
CME credit hours: 2.0
Osteoporotic fractures affect millions of postmen-opausal women, and can have a substantial negative effect on daily functioning and quality of life. These fractures are associated with an increased risk of future fracture, clinical complications, and a higher risk of death. However, osteoporosis remains woefully under-diagnosed and undertreated, even among patients who already have fractures. When treatment is provided, adherence and persistence are often suboptimal, reducing the likelihood of a positive outcome.

Congestion in Acute Decompensated Heart Failure: A Case Based Discussion
Faculty: Mihai Gheorghiade, MD, FACC | Clyde W. Yancy, MD, FACC, FAHA, FACP
CME credit hours: 1.5
This program reviews the definition, demographics, and risks of acute decompensated heart failure. Our expert faculty will discuss the strengths, limitations and concerns of standard therapies such as diuretics, vasodilators, inotropes, and natriuretic peptides. The faculty will also discuss emerging therapies including ultrafiltration, adenosine antagonists, and vasopressin receptor antagonists. This activity aims to give cardiologists and other cardiac care givers a good understanding of how to optimize medical therapy for their patients with acute decompensated heart failure, with an emphasis on relieving symptoms.

ACS Patients and Antiplatelet Resistance: Where We Are and Where We're Going.
Faculty: Deepak L. Bhatt, MD | Cindy L. Grines, MD | Peter B. Berger, MD
CME / CE credit hour: 1.5
Myocardial ischemia secondary to acute restrictions in coronary artery blood flow leads to acute coronary syndromes (ACS). Dual antiplatelet therapy with aspirin and clopidogrel is the standard of care for patients with ACS. However, resistance to these agents is associated with adverse clinical events, and is of great concern to clinicians. This educational program will review clinical data pertinent to the current state of antiplatelet therapy for the management of patients with ACS.

Generic Substitution and Therapeutic Equivalence of Antiepileptic Drugs: Clinical and Pharmacoeconomic Issues in Epilepsy Management
A Priority Report
Faculty: John M. Pellock, MD | Andrew J. Pultz, Jr, PharmD, RPh
CME / CE credit hour: 1.0
The issue of generic drug substitution is complex and often poorly understood by physicians and pharmacists. Although the FDA requires that two drugs are similar as demonstrated by bioequivalence data, therapeutic equivalence (or therapeutic effectiveness) and bioequivalence are not necessarily the same. In the case of antiepileptic drugs (AEDs), the therapeutic range over which they are effective may be narrow and, although generic substitution of AEDs may be appropriate for some patients with epilepsy, it may represent suboptimal care for others. This program will give an overview of these and other important issues associated with generic substitution of AEDs.

The Practical and Regulatory Perspective of Bioequivalence
Faculty: Sandra L. Kane-Gill, PharmD, MSC | Joseph F. Dasta, MS, FCCM, FCCP | Nicholas M. Fleischer, RPh, PhD. | Mary Lea Gora-Harper, PharmD, FASHP
CE Credit hour: 1.0
Bioequivalence needs to be determined before an automatic substitution of products or product dosage forms can be made.  When automatic substitutions between brand and generic, generic and generic or between dosage forms are made, clinicians need to be aware of the potential clinical and regulatory issues associated with these substitutions. While product interchange between brand and generic medications, generic and generic medications or different forms of the same product is not typically a problem, this activity will highlight some examples of clinical concerns and related regulation considerations.  It will also provide some direction on obtaining relevant information of bioequivalence.

www.Arcmesa.org is dedicated to helping maintain and improve quality of life through medical education. All CME / CE activities are created in accordance with the latest industry policies and guidelines. From live symposia coverage to print monographs and CD ROMs, all our activities are free and available online at Arcmesa.org.

More >>>

All information content within shall be considered confidential property of ArcMesa Educators, LLC
and should not be disclosed or redistributed to third parties without express permission.